FierceBiotechOriginal article
{"a":[{"_":"MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial","$":{"href":"/biotech/moonlakes-nanobody-candidate-boosts-all-clinical-endpoints-phase-3-psoriatic-arthritis","hreflang":"en"}}]}
Phase 3positivesonelokimabPositive
AI Analysis
Summary
MoonLake Immunotherapeutics announced positive Phase 3 data for sonelokimab, its nanobody candidate, in patients with psoriatic arthritis, with the drug meeting all clinical endpoints.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
nanobody candidate boosted all clinical endpoints in phase 3 trial
Importance:7/10
Sentiment:
0.85
nanobodypsoriatic arthritisphase 3positive data
Read the original article
Published by FierceBiotech on August 10, 2026 10:00 AM